BIOGEN INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
BIOGEN INC. (BIIB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 1.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-02-06
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for the quarter ending 2020-09-30 was -0.60%.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for the quarter ending 2020-06-30 was 0.10%, a 75.00% decline year-over-year.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for the quarter ending 2020-03-31 was 0.20%, a 50.00% decline year-over-year.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for the quarter ending 2019-09-30 was -0.10%, a 133.33% decline year-over-year.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 1.10%.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2019 was 0.20%, a 33.33% decline from fiscal 2018.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2018 was 0.30%, a 57.14% decline from fiscal 2017.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2017 was 0.70%, a 40.00% increase from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 3 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 6 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 9 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1.10% 10-K · filed 2026-02-06 | |||||||
| 2020-09-30 | -0.60% 10-Q · filed 2020-10-21 | 0.00% 10-Q · filed 2020-10-21 | ||||||
| 2020-06-30 | 0.10% 10-Q · filed 2020-07-22 | 0.10% 10-Q · filed 2020-07-22 | ||||||
| 2020-03-31 | 0.20% 10-Q · filed 2020-04-23 | |||||||
| 2019-12-31 | 0.20% 10-K · filed 2020-02-06 | |||||||
| 2019-09-30 | -0.10% 10-Q · filed 2020-10-21 | 0.20% 10-Q · filed 2020-10-21 | ||||||
| 2019-06-30 | 0.40% 10-Q · filed 2020-07-22 | 0.30% 10-Q · filed 2020-07-22 | ||||||
| 2019-03-31 | 0.40% 10-Q · filed 2020-04-23 | |||||||
| 2018-12-31 | 0.30% 10-K · filed 2020-02-06 | |||||||
| 2018-09-30 | 0.30% 10-Q · filed 2019-10-22 | 0.30% 10-Q · filed 2019-10-22 | ||||||
| 2018-06-30 | 0.40% 10-Q · filed 2019-07-24 | 0.40% 10-Q · filed 2019-07-24 | ||||||
| 2018-03-31 | 0.40% 10-Q · filed 2019-04-24 | |||||||
| 2017-12-31 | 0.70% 10-K · filed 2020-02-06 | |||||||
| 2017-09-30 | 0.60% 10-Q · filed 2018-10-23 | 0.70% 10-Q · filed 2018-10-23 | ||||||
| 2017-06-30 | 0.70% 10-Q · filed 2018-07-24 | 0.70% 10-Q · filed 2018-07-24 | ||||||
| 2017-03-31 | 0.70% 10-Q · filed 2018-04-24 | |||||||
| 2016-12-31 | 0.50% 10-K · filed 2019-02-06 | |||||||
| 2016-09-30 | 0.20% 10-Q · filed 2017-10-24 | 0.50% 10-Q · filed 2017-10-24 | ||||||
| 2016-06-30 | 0.60% 10-Q · filed 2017-07-25 | 0.60% 10-Q · filed 2017-07-25 | ||||||
| 2016-03-31 | 0.60% 10-Q · filed 2017-04-25 | |||||||
| 2015-12-31 | 0.70% 10-K · filed 2018-02-01 | |||||||
| 2015-09-30 | 0.50% 10-Q · filed 2016-10-26 | 0.60% 10-Q · filed 2016-10-26 | ||||||
| 2015-06-30 | 0.90% 10-Q · filed 2016-07-21 | 0.70% 10-Q · filed 2016-07-21 | ||||||
| 2015-03-31 | 0.60% 10-Q · filed 2016-04-21 | |||||||
| 2014-12-31 | 0.50% 10-K · filed 2017-02-02 | |||||||
| 2014-09-30 | 0.40% 10-Q · filed 2015-10-21 | 0.40% 10-Q · filed 2015-10-21 | ||||||
| 2014-06-30 | 0.40% 10-Q · filed 2015-07-24 | 0.40% 10-Q · filed 2015-07-24 | ||||||
| 2014-03-31 | 0.30% 10-Q · filed 2015-04-24 | |||||||
| 2013-12-31 | 0.80% 10-K · filed 2016-02-03 | |||||||
| 2013-09-30 | -0.30% 10-Q · filed 2014-10-22 | 1.00% 10-Q · filed 2014-10-22 | ||||||
| 2013-06-30 | -1.00% 10-Q · filed 2014-07-23 | 1.80% 10-Q · filed 2014-07-23 | ||||||
| 2013-03-31 | 5.50% 10-Q · filed 2014-04-23 | |||||||
| 2012-12-31 | -0.40% 10-K · filed 2015-02-04 | -2.50% 10-K · filed 2013-02-05 | ||||||
| 2012-09-30 | 0.40% 10-Q · filed 2013-10-28 | -2.10% 10-Q · filed 2012-10-25 | -0.40% 10-Q · filed 2013-10-28 | -2.70% 10-Q · filed 2012-10-25 | ||||
| 2012-06-30 | -0.30% 10-Q · filed 2013-07-25 | -2.40% 10-Q · filed 2012-07-24 | -1.00% 10-Q · filed 2013-07-25 | -3.10% 10-Q · filed 2012-07-24 | ||||
| 2012-03-31 | -1.80% 10-Q · filed 2013-04-25 | -3.90% 10-Q · filed 2012-05-01 | ||||||
| 2011-12-31 | 0.30% 10-K · filed 2014-02-06 | -1.20% 10-K · filed 2012-02-03 | ||||||
| 2011-09-30 | -1.20% 10-Q · filed 2012-10-25 | -1.20% 10-Q · filed 2012-10-25 | ||||||
| 2011-06-30 | -1.10% 10-Q · filed 2012-07-24 | -1.20% 10-Q · filed 2012-07-24 | ||||||
| 2011-03-31 | -1.30% 10-Q · filed 2012-05-01 | |||||||
| 2010-12-31 | -2.00% 10-K · filed 2013-02-05 | |||||||
| 2010-09-30 | -3.80% 10-Q · filed 2011-10-28 | -2.10% 10-Q · filed 2011-10-28 | ||||||
| 2010-06-30 | -1.70% 10-Q · filed 2011-07-26 | -1.70% 10-Q · filed 2011-07-26 | ||||||
| 2009-12-31 | -1.30% 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |